



SPARC/Sec/SE/2024-25/063

January 17, 2025

To,

**National Stock Exchange of India Ltd.,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051.

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.

*Scrip Symbol: SPARC*

*Scrip Code: 532872*

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), we would like to inform you that Dr. Venkata Palle, Executive Vice President - Global Head Drug Discovery & Preclinical Development of the Company have been transferred to SPARCLIFE Inc., Wholly Owned Subsidiary of the Company designated as Executive Vice President - Small Molecules.

The details as required under Regulation 30 read with Part A of Schedule III of the SEBI LODR, is enclosed herewith as **Annexure A**.

The Intimation is also available on the website of the Company at <https://sparc.life>

You are requested to take the same on record.

Yours faithfully,

**For Sun Pharma Advanced Research Company Limited**

**Kajal Damania**  
**Company Secretary and Compliance Officer**

Encl: As above

### Annexure A

SR.NO	PARTICULARS	DETAILS
1	Name of Senior Management Personnel	Dr. Venkata Palle
2	Designation in the SPARCLIFE Inc.	Executive Vice President - Small Molecules
2	Reason for change	<p>Dr. Palle is relocating to the United States (US) for personal reasons. To retain his expertise, it has been decided to transfer him to SPARCLIFE Inc., Wholly Owned Subsidiary of the Company situated at Cranbury, NJ 08512.</p> <p>He will oversee scientific strategy and the small molecule discovery programs</p> <p>Additionally, it has been decided that he will no longer be a part of the Senior Management Team of the SPARC.</p>
3	Date of Appointment/ transfer	January 17, 2025
4	Brief profile (in case of appointment)	NA
5	Disclosure of Relationship between Directors (in case of appointment)	NA